Eosinophilic Esophagitis Treatment for Patients | DUPIXENT® (dupilumab)

THE FIRST FDA-APPROVED TREATMENT FOR EoE PATIENTS AS YOUNG AS 1 YEAR¹

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year
and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).¹

TRANSFORM THE WAY
YOU MANAGE EoE

Discover clinical, histologic,
and
endoscopic results^1-3

FDA-APPROVED in children as
young as 1 year with EoE (≥15 kg)¹

Not actual patients.

FDA-APPROVED in children as
young as 1 year with EoE (≥15 kg)¹

EoE is a condition driven in part by chronic type 2 inflammation and requires a long-term approach. Only DUPIXENT directly inhibits the signaling of two of the key drivers of type 2 inflammation, IL-4 and IL-13.^1,4,5

The mechanism of dupilumab action has not been definitively established.¹

To see the science behind DUPIXENT, visit our MOA page

FOR YOUR EoE PATIENTS AS YOUNG AS 1 YEAR TO adults, learn how to properly administer DUPIXENT

Dosing & Administration

Looking for a SPECIALIST partner for your EoE patients?

Find a specialist

DUPIXENT MyWay® is a patient support
program
that can help
enable access to
DUPIXENT
and offers financial assistance
for
eligible
patients, one-on-one nursing
support, and more.

LEARN HOW WE CAN HELP

*DUPIXENT MyWay* ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field
Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.